Found: 71
Select item for more details and to access through your institution.
Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours.
- Published in:
- BJU International, 2018, v. 122, n. 5, p. 814, doi. 10.1111/bju.14372
- By:
- Publication type:
- Article
Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1399802
- By:
- Publication type:
- Article
Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer.
- Published in:
- Clinical Colorectal Cancer, 2021, v. 20, n. 4, p. 334, doi. 10.1016/j.clcc.2021.07.004
- By:
- Publication type:
- Article
Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study.
- Published in:
- PLoS ONE, 2021, v. 16, n. 12, p. 1, doi. 10.1371/journal.pone.0259272
- By:
- Publication type:
- Article
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response.
- Published in:
- AUANews, 2023, p. 23
- By:
- Publication type:
- Article
Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2022, v. 41, n. 1, p. 1, doi. 10.1186/s13046-021-02236-7
- By:
- Publication type:
- Article
The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National Survey.
- Published in:
- Current Oncology, 2023, v. 30, n. 7, p. 6166, doi. 10.3390/curroncol30070458
- By:
- Publication type:
- Article
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults.
- Published in:
- Current Oncology, 2021, v. 28, n. 1, p. 523, doi. 10.3390/curroncol28010053
- By:
- Publication type:
- Article
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer.
- Published in:
- Current Oncology, 2021, v. 28, n. 1, p. 107, doi. 10.3390/curroncol28010014
- By:
- Publication type:
- Article
Prospective manipulation of the gut microbiome with microbial ecosystem therapeutic 4 (MET4) in HPV-related locoregionally-advanced oropharyngeal cancer squamous cell carcinoma (LA-OPSCC) undergoing primary chemoradiation: ROMA2 study.
- Published in:
- British Journal of Cancer, 2024, v. 130, n. 12, p. 1936, doi. 10.1038/s41416-024-02701-y
- By:
- Publication type:
- Article
A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events.
- Published in:
- British Journal of Cancer, 2023, v. 129, n. 4, p. 612, doi. 10.1038/s41416-023-02307-w
- By:
- Publication type:
- Article
The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma.
- Published in:
- British Journal of Cancer, 2023, v. 128, n. 10, p. 1888, doi. 10.1038/s41416-023-02166-5
- By:
- Publication type:
- Article
Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study).
- Published in:
- 2021
- By:
- Publication type:
- journal article
Evaluating the impact of early identification of asymptomatic brain metastases in metastatic renal cell carcinoma.
- Published in:
- Cancer Reports, 2023, v. 6, n. 3, p. 1, doi. 10.1002/cnr2.1763
- By:
- Publication type:
- Article
Out‐of‐pocket costs associated with head and neck cancer treatment.
- Published in:
- Cancer Reports, 2022, v. 5, n. 7, p. 1, doi. 10.1002/cnr2.1528
- By:
- Publication type:
- Article
Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Screening for Nasopharyngeal Cancer in High-Risk Populations: A Small Price to Pay for Early Disease Identification?
- Published in:
- 2021
- By:
- Publication type:
- journal article
Development of a radiomic signature for predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
- Published in:
- Canadian Urological Association Journal, 2022, v. 16, n. 3, p. E113, doi. 10.5489/cuaj.7294
- By:
- Publication type:
- Article
Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma.
- Published in:
- Canadian Urological Association Journal, 2022, v. 16, n. 2, p. E94, doi. 10.5489/cuaj.7467
- By:
- Publication type:
- Article
Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma.
- Published in:
- Canadian Urological Association Journal, 2021, v. 15, n. 9, p. 1, doi. 10.5489/cuaj.7467
- By:
- Publication type:
- Article
Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021.
- Published in:
- Canadian Urological Association Journal, 2021, v. 15, n. 4, p. 84, doi. 10.5489/cuaj.7245
- By:
- Publication type:
- Article
Clinical dilemmas in local and regional testis cancer.
- Published in:
- Canadian Urological Association Journal, 2021, v. 15, n. 1, p. E58, doi. 10.5489/cuaj.6913
- By:
- Publication type:
- Article
Controversies in the management of clinical stage 1 testis cancer.
- Published in:
- Canadian Urological Association Journal, 2020, v. 14, n. 11, p. E537, doi. 10.5489/cuaj.6722
- By:
- Publication type:
- Article
A Canadian approach to the regionalization of testis cancer: A review.
- Published in:
- Canadian Urological Association Journal, 2020, v. 14, n. 10, p. 1, doi. 10.5489/cuaj.6268
- By:
- Publication type:
- Article
Chemotherapy intensification for first-line treatment of poor-prognosis metastatic germ cell cancer is not yet ready for prime time.
- Published in:
- Canadian Urological Association Journal, 2020, v. 14, n. 2, p. 48, doi. 10.5489/cuaj.6407
- By:
- Publication type:
- Article
Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach.
- Published in:
- Canadian Urological Association Journal, 2018, v. 12, n. 2, p. 59, doi. 10.5489/cuaj.4531
- By:
- Publication type:
- Article
Salvage chemotherapy for metastatic germ cell tumours: The known unknowns.
- Published in:
- 2012
- By:
- Publication type:
- Opinion
Early phase clinical trials to identify optimal dosing and safety.
- Published in:
- Molecular Oncology, 2015, v. 9, n. 5, p. 997, doi. 10.1016/j.molonc.2014.07.025
- By:
- Publication type:
- Article
Real‐World Assessment of Clinical Outcomes Among First‐Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
- Published in:
- Oncologist, 2020, v. 25, n. 5, p. 422, doi. 10.1634/theoncologist.2019-0605
- By:
- Publication type:
- Article
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration‐Resistant Prostate Cancer (mCRPC).
- Published in:
- Oncologist, 2019, v. 24, n. 9, p. 1188, doi. 10.1634/theoncologist.2018-0621
- By:
- Publication type:
- Article
Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era.
- Published in:
- Oncologist, 2019, v. 24, n. 7, p. e518, doi. 10.1634/theoncologist.2018-0808
- By:
- Publication type:
- Article
Feasibility Assessment of Using the Complete Patient‐Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO‐CTCAE) Item Library.
- Published in:
- Oncologist, 2019, v. 24, n. 4, p. e146, doi. 10.1634/theoncologist.2018-0332
- By:
- Publication type:
- Article
Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials.
- Published in:
- Oncologist, 2015, v. 20, n. 6, p. 653, doi. 10.1634/theoncologist.2015-0008
- By:
- Publication type:
- Article
Cancer patients' experiences with immune checkpoint modulators: A qualitative study.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 9, p. 3015, doi. 10.1002/cam4.2940
- By:
- Publication type:
- Article
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-25432-7
- By:
- Publication type:
- Article
Comparison of outcomes for Hispanic and non‐Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 11, p. 2003, doi. 10.1002/cncr.35216
- By:
- Publication type:
- Article
Longitudinal health utility and symptom‐toxicity trajectories in patients with head and neck cancers.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 3, p. 497, doi. 10.1002/cncr.33936
- By:
- Publication type:
- Article
Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen‐receptor–targeted therapy for metastatic castration‐resistant prostate cancer.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 14, p. 2587, doi. 10.1002/cncr.33523
- By:
- Publication type:
- Article
Health‐related quality‐of‐life assessment of patients with solid tumors on immuno‐oncology therapies.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 9, p. 1360, doi. 10.1002/cncr.33457
- By:
- Publication type:
- Article
Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 3, p. 241, doi. 10.1007/s10637-024-01428-0
- By:
- Publication type:
- Article
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 1, p. 145, doi. 10.1007/s10637-023-01410-2
- By:
- Publication type:
- Article
Tumour heterogeneity in the clinic.
- Published in:
- Nature, 2013, v. 501, n. 7467, p. 355, doi. 10.1038/nature12627
- By:
- Publication type:
- Article
Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-31199-2
- By:
- Publication type:
- Article
Determinants of the recommended phase 2 dose of molecular targeted agents.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Single institution retrospective review of perioperative chemotherapy in adult and adolescent patients with operable osteosarcoma.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2016, v. 12, n. 2, p. e222, doi. 10.1111/ajco.12167
- By:
- Publication type:
- Article
The Survival Outcomes of the Metastatic Nonclear Cell Renal Cell Carcinoma in the Immunotherapy Era: Princess Margaret Cancer Centre Experience.
- Published in:
- Journal of Kidney Cancer & VHL, 2024, v. 11, n. 1, p. 41, doi. 10.15586/jkcvhl.v11i1.307
- By:
- Publication type:
- Article